Research progress of dydrogesterone in the treatment of endometriosis

• Tang W.
• Zhu X.
• Bian L.
• Bin Zhang

Abstract

Endometriosis is a common gynecological disease among women of reproductive age. It is a chronic estrogen and progestin related inflammatory disease. At present, the main treatments for endometriosis are drug therapy and surgery. In drug therapy, progesterone is listed as the first-line recommendation in multinational guidelines. Dydrogesterone, as an oral reversal progesterone, can slow down the metabolism of progesterone, inhibit angiogenesis and extracellular matrix degradation to inhibit the proliferation of the ectopic endometrium, induce the atrophy of the ectopic endometrium through the pro-apoptotic pathway, and treat endometriosis through multiple mechanisms of regulating inflammatory factors to reduce inflammation. Clinically, dydrogesterone treatment of endometriosis can relieve patients’ symptoms, promote fertility, be used in combination, and is safe. This article will review the mechanism and clinical application of dydrogesterone in the treatment of endometriosis.

Keywords: dydrogesterone; endometriosis; mechanism; clinical research

References

1. Brown J., Pan A., Hart R.J. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010; 2010 (12): CD008475.

2. Brown J., Kives S., Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2012; 2012 (3): CD002122.

3. Bulun S.E. Endometriosis. N Engl J Med. 2009; 360 (3): 268–79.

4. Bulun S.E., Cheng Y.H., Yin P., Imir G., Utsunomiya H., Attar E., et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006; 248 (1–2): 94–103.

5. Klemmt P.A.B., Starzinski-Powitz A. Molecular and cellular pathogenesis of endometriosis. Curr Womens Health Rev. 2018; 14 (2): 106–16.

6. Beranic N., Lanisnik R.T. Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013; 202 (1–3): 218–25.

7. Rizner T.L. Estrogen metabolism and action in endometriosis. Mol Cell Endocrinol. 2009; 307 (1–2): 8–18.

8. Hevir N., Vouk K., Sinkovec J., Ribic-Pucelj M., Rizner T.L. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. Chem Biol Interact. 2011; 191 (1–3): 217–26.

9. Beranizc N., Gobec S., Rizzner T.L. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011; 191 (1–3): 227–33.

10. Beranizc N., Rizzner T.L. Effects of progestins on local estradiol biosynthesis and action in the Z-12 endometriotic epithelial cell line. J Steroid Biochem Mol Biol. 2012; 132 (3–5): 303–10.

11. Rizzner T.L., Penning T.M. Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis. Pharmacol Res. 2020; 152: 104446.

12. King R.J., Whitehead M.I. Assessment of the potency of orally administered progestins in women. Fertil Steril. 1986; 46 (6): 1062–6.

13. Jiang L., Yan Y., Liu Z., Wang Y. Inflammation and endometriosis. Front Biosci (Landmark Ed). 2016; 21 (5): 941–8.

14. Rana N., Braun D.P., House R., Gebel H., Rotman C., Dmowski W.P. Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis. Fertil Steril. 1996; 65 (5): 925–30.

15. Kats R., Collette T., Metz C.N., Akoum A. Marked elevation of macrophage migration inhibitory factor in the peritoneal fluid of women with endometriosis. Fertil Steril. 2002; 78 (1): 69–76.

16. Arici A., Oral E., Attar E., Tazuke S.I., Olive D.L. Monocyte chemotactic protein-1 concentration in peritoneal fluid of women with endometriosis and its modulation of expression in mesothelial cells. Fertil Steril. 1997; 67 (6): 1065–72.

17. Burney R.O., Giudice L.C. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012; 98 (3): 511–9.

18. Rakhila H., Al-Akoum M., Doillon C., Lacroix-Pepin N., Leboeuf M., Lemyre M., et al. Augmented angiogenic factors expression via FP signaling pathways in peritoneal endometriosis. J Clin Endocrinol Metab. 2016; 101 (12): 4752–63.

19. Gonzalez-Ramos R., Donnez J., Defr’re S., Leclercq I., Squifflet J., Lousse J.C., et al. Nuclear factor-kappa B is constitutively activated in peritoneal endometriosis. Mol Hum Reprod. 2007; 13 (7): 503–9.

20. Horie S., Harada T., Mitsunari M., Taniguchi F., Iwabe T., Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril. 2005; 83 (5): 1530–5.

21. Raghupathy R., Al Mutawa E., Makhseed M., Azizieh F., Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG. 2005; 112 (8): 1096–101.

22. Kyama C.M., Mihalyi A., Simsa P., Mwenda J.M., Tomassetti C., Meuleman C., et al. Non-steroidal targets in the diagnosis and treatment of endometriosis. Curr Med Chem. 2008; 15 (10): 1006–17.

23. Simoncini T., Caruso A., Giretti M.S., Scorticati C., Fu X.D., Garibaldi S., et al. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril. 2006; 86 (4 suppl): 1235–42.

24. Schweppe K.W. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009; 65 (suppl 1): S23–7.

25. Tariverdian N., Rücke M., Szekeres-Bartho J., Blois S.M., Karpf E.F., Sedlmayr P., et al. Neuroendocrine circuitry and endometriosis: progesterone derivative dampens corticotropin-releasing hormone-induced inflammation by peritoneal cells in vitro. J Mol Med (Berl). 2010; 88 (3): 267–78.

26. Laschke M.W., Giebels C., Menger M.D. Vasculogenesis: a new piece of the endometriosis puzzle. Hum Reprod Update. 2011; 17 (5): 628–36.

27. MacLaughlan S.D., Palomino W.A., Mo B., Lewis T.D., Lininger R.A., Lessey B.A. Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium. Obstet Gynecol. 2007; 110 (1): 146–54.

28. Goteri G., Lucarini G., Montik N., Zizzi A., Stramazzotti D., Fabris G., et al. Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor-1alpha (HIF-1alpha), and microvessel density in endometrial tissue in women with adenomyosis. Int J Gynecol Pathol. 2009; 28 (2): 157–63.

29. Laschke M.W., Menger M.D. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update. 2007; 13 (4): 331–42.

30. Zhao Y., Li Q., Katzenellenbogen B.S., Lau L.F., Taylor R.N., Bagchi I.C., et al. Estrogen-induced CCN1 is critical for establishment of endometriosis-like lesions in mice. Mol Endocrinol. 2014; 28 (12): 1934–47.

31. Monckedieck V., Sannecke C., Husen B., Kumbartski M., Kimmig R., Totsch M., et al. Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model. Mol Hum Reprod 2009; 15 (10): 633–43.

32. Pitsos M., Kanakas N. The role of matrix metalloproteinases in the pathogenesis of endometriosis. Reprod Sci. 2009; 16 (8): 717–26.

33. Samartzis E.P., Fink D., Stucki M., Imesch P. Doxycycline reduces MMP-2 activity and inhibits invasion of 12Z epithelial endometriotic cells as well as MMP-2 and -9 activity in primary endometriotic stromal cells in vitro. Reprod Biol Endocrinol. 2019; 17 (1): 38.

34. Yoshino O., Osuga Y., Hirota Y., Koga K., Hirata T., Harada M., et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol. 2004; 52 (5): 306–11.

35. Valentijn A.J., Saretzki G., Tempest N., Critchley H.O., Hapangama D.K. Human endometrial epithelial telomerase is important for epithelial proliferation and glandular formation with potential implications in endometriosis. Hum Reprod. 2015; 30 (12): 2816–28.

36. Song Y., Su R.W., Joshi N.R., Kim T.H., Lessey B.A., Jeong J.W., et al. Interleukin-6 (IL-6) activates the NOTCH1 signaling pathway through E-proteins in endometriotic lesions. J Clin Endocrinol Metab. 2020; 105 (5): 1316–26.

37. Liang B., Wu L., Xu H., Cheung C.W., Fung W.Y., Wong S.W., et al. Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice. Reprod Biol Endocrinol. 2018; 16 (1): 32.

38. Reis F.M., Petraglia F., Taylor R.N. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013; 19 (4): 406–18.

39. Wu M.H., Lin S.C., Hsiao K.Y., Tsai S.J. Hypoxia-inhibited dual-specificity phosphatase-2 expression in endometriotic cells regulates cyclooxygenase-2 expression. J Pathol. 2011; 225 (3): 390–400.

40. Ma Y., Shen A., Li C., Xu S., Guo H., Zou S. Targeted interruption of COX-2 gene by siRNA inhibits the expression of VEGF, MMP-9, the activity of COX-2 and stimulates the apoptosis in eutopic, ectopic endometrial stromal cells of women with endometriosis. Zhonghua Fu Chan Ke Za Zhi. 2015; 50 (10): 770–6.

41. Taniguchi F., Ota I., Iba Y., Toda T., Tagashira Y., Ohata Y., et al. The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: an open-label multicenter clinical study. J Obstet Gynaecol Res. 2019; 45 (1): 168–75.

42. Sukhikh G.T., Adamyan L.V., Dubrovina S.O., Baranov I.I., Bezhenar V.F., Kozachenko A.V., et al. Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis: results of the ORCHIDEA study. Fertil Steril. 2021; 116 (6): 1568–77.

43. Trivedi P., Selvaraj K., Mahapatra P.D., Srivastava S., Malik S. Effective post- laparoscopic treatment of endometriosis with dydrogesterone. Gynecol Endocrinol. 2007; 23 (suppl 1): 73–6.

44. Overton C.E., Lindsay P.C., Johal B., Collins S.A., Siddle N.C., Shaw R.W., et al. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril. 1994; 62 (4): 701–7.

45. Makhmudova G.M., Nazhmutdinova D.K., Gafarova D., Lukmanova I.D. Efficacy of duphaston treatment in women with endometriosis after reconstructive surgery. Akush Ginekol. 2003; 42 (4): 42–6.

46. Orazov M.R., Radzinsky V.Y., Khamoshina M.B. The efficacy of combined management of endometriosis-associated infertility. Int J Pharm Res. 2019; 11 (3): 1001–6.

47. Kitawaki J., Koga K., Kanzo T., Momoeda M. An assessment of the efficacy and safety of dydrogesterone in women with ovarian endometrioma: an open-label multicenter clinical study. Reprod Med Biol. 2021; 20 (3): 345–51.

48. Yalcin Bahat P., Yücel B., Yuksel Ozgor B., Kadirogullari P., Topbas Selcuki N.F., Qakmak K., et al. The effect of dydrogesterone on sexual function in endometriosis. J Obstet Gynaecol. 2022; 42 (5): 1276–9.

49. Counseller V.S., Crenshaw J.L. Jr. A clinical and surgical review of endometriosis. Am J Obstet Gynecol. 1951; 62 (4): 930–42.

50. Barnhart K., Dunsmoor-Su R., Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril. 2002; 77 (6): 1148–55.

51. Harb H.M., Gallos I.D., Chu J., Harb M., Coomarasamy A. The effect of endometriosis on in vitro fertilisation outcome: a systematic review and meta-analysis. BJOG. 2013; 120 (11): 1308–20.

52. Abu-Musa A., Hannoun A., Khalil A., Masaad Z., Karam K. Artificial endometrial preparation for oocyte donation using synthetic estrogen and progestogen. Clin Exp Obstet Gynecol. 1998; 25 (3): 83–5.

53. Moroni R., Vieira C., Ferriani R., Candido-Dos-Reis F., Brito L. Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res. 2014; 4 (suppl 3): S185–92.

54. Sun S., Zhang H., Zhong P., Xu Z. The Effect of letrozole combined with dydrogesterone for endometriosis in China: a meta-analysis. Biomed Res Int. 2021; 2021: 9946060.

55. Zondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N Engl J Med. 2020; 382 (13): 1244–56.

56. Zou S., Long Q., Zhang S., Han Y., Zhang W. Oral continuous combined 0.5 mg estradiol valerate and 5 mg dydrogesterone as daily add-back therapy during postoperative GnRH agonist treatment for endometriosis in Chinese women. Int J Clin Exp Med. 2013; 6 (1): 67–73.

57. Rizzner T.L., Brozzizc P., Doucette C., Turek-Etienne T., Müller-Vieira U., Sonneveld E., et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011; 76 (6): 607–15.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)